The short version of circadian rhythm fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-15. Anything still debated is marked as such rather than presented as settled.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
increasing insulin sensitivity reducing hyperandrogenism reducing the risk of metabolic disease restoring follicle-stimulating hormone (FSH) to luteinizing hormone (LH) ratio and menstrual cycle regularization increasing the chance of success in patients seeking reproductive therapy Combination therapy with myo-inositol (MI) and D-chiro-inositol (DCI) has also been extensively clinically explored, with the balance of each stereroisomer in circulation gaining popularity as a clinical target. Insulin stimulates the irreversible conversion of MI to DCI by an NADPH-dependent epimerase, and both hyperinsulinemia and elevated DCI are clinically evident in 70% of PMOS patients. The plasmatic ratio of MI and DCI in healthy subjects is 40:1 MI to DCI respectively, and using this ratio as a clinical target shows the same efficacy of MI alone but in a shorter time. In addition, the physiological ratio maintains healthy oocyte quality in patients using DCI for fertility therapy, whereas DCI monotherapy is known to impair oocyte quality. Disturbances in intracellular MI and DCI ratios are linked to an "inositol resistance" phenotype, where MI monotherapy is less effective. MI and α-lactalbumin combination therapy increases myo-inositol plasmatic content in inositol-resistant patients with a relative improvement of hormonal and metabolic parameters.
== History of slow cooking == Long before the invention of electric cooking devices, cultures across Europe, Asia and North Africa relied on heavy cast iron Dutch ovens and pottery, such as the Moroccan tagine. to tenderise tough cuts of meat and simmer pulses over low and sustained heat. These traditional non-electric methods frequently utilised the residual heat of brick hearth ovens or dying wood fires. The mastery of slow cooking stems from a universal culinary challenge: transforming fibrous and collagen rich cuts of meat and hard legumes into digestible and nourishing meals without temperature controls. Across diverse geographies, cooks discovered that sustained and gentle thermal energy breaks down connective tissue over hours. This renders tough ingredients meltingly tender while infusing them with concentrated flavours.
2 HNO3 ⇌ H2NO+3 + NO−3 ⇌ H2O + [NO2]+ + [NO3]− Two hydrates, HNO3·H2O and HNO3·3H2O, are known that can be crystallised. It is a strong acid and concentrated solutions are strong oxidising agents, though gold, platinum, rhodium, and iridium are immune to attack. A 3:1 mixture of concentrated hydrochloric acid and nitric acid, called aqua regia, is still stronger and successfully dissolves gold and platinum, because free chlorine and nitrosyl chloride are formed and chloride anions can form strong complexes. In concentrated sulfuric acid, nitric acid is protonated to form nitronium, which can act as an electrophile for aromatic nitration:
Sources: en.wikipedia.org
== Pharmaceuticals == The first three nonbenzodiazepine drugs to enter the market were the "Z-drugs": zopiclone, zolpidem and zaleplon. Initially thought to compared to the benzodiazepines, have less of a tendency to induce physical dependence and addiction, although these issues can still become a problem. This has led to the Z-drugs becoming widely prescribed for the treatment of insomnia particularly in elderly patients. Long-term use is not recommended as tolerance and addiction can occur. Zolpidem and zaleplon are, in the US, indicated for 7–10 days of use only. Longer periods of use lead to loss of efficacy from tolerance. Tolerance has also been demonstrated with zopiclone, which is indicated for a maximum of 4 weeks of use in New Zealand.
Pulsed electric field (PEF) electroporation is a method for processing cells by means of brief pulses of a strong electric field. PEF holds potential as a type of low-temperature alternative pasteurization process for sterilizing food products. In PEF processing, a substance is placed between two electrodes, then the pulsed electric field is applied. The electric field enlarges the pores of the cell membranes, which kills the cells and releases their contents. PEF for food processing is a developing technology still being researched. There have been limited industrial applications of PEF processing for the pasteurization of fruit juices. To date, several PEF treated juices are available on the market in Europe. Furthermore, for several years a juice pasteurization application in the US has used PEF. For cell disintegration purposes especially potato processors show great interest in PEF technology as an efficient alternative for their preheaters. Potato applications are already operational in the US and Canada. There are also commercial PEF potato applications in various countries in Europe, as well as in Australia, India, and China.
==== Insurances Covering Gender Affirmative Care ==== Numerous insurances within the United States cover gender affirming care, which includes hormone replacement therapy (HRT) and surgery. However, this coverage is conditional and dependent on many factors, such as plan benefits, employer, and the state. In California most insurers are forbidden from banning gender affirming care coverage; however, insurers in other states don't have this restriction and can exclude coverage of gender affirming care. Each specific plan and policy will specify the coverage of gender affirming care. Most insurers covering gender affirming care will cover generic and FDA approved hormone replacement therapy. If a clinician recommends a brand name hormone replacement therapy, insurance will conditionally accept it based on recommendation, cost, policy, and healthcare needs. Some insurers that cover gender affirming care include Anthem Blue Cross and Blue Shield, Cigna, Aetna, Medicare, Tricare and UnitedHealthcare.
Sources: en.wikipedia.org
Representatives Ro Khanna, a California Democrat, Thomas Massie, a Kentucky Republican and Marjorie Taylor Greene, a Georgia Republican and close ally of Trump, urged the House of Representatives to vote to release the full files. House Republican leaders offered an alternative vote to continue investigation by the House Oversight Committee. On September 3, President Trump spoke to reporters from the Oval Office, and said that the call for release of files is a "Democrat hoax that never ends". Similarly, CNN states that Democrats have "sought to weaponize the Epstein issue against Trump and the GOP in recent weeks, trying to force votes that would put vulnerable Republicans in difficult positions. But the tone of Wednesday's press conference was far less partisan." On October 7, Attorney General Bondi testified before the Senate Judiciary Committee and BBC drew five "takeaways" including "3. Bondi keen to focus on crime" and "4. But Democrats focus on Epstein". However, Senator John Kennedy (Republican - Louisiana) repeated comments from Commerce Secretary Howard Lutnick that Epstein was "the greatest blackmailer ever". On November 12, 2025, the petition to force a House vote for the release of the Epstein files by the Department of Justice secured the final required signature from Democratic Rep. Adelita Grijalva, the latter being sworn in for her position after the end of the October 2025 government shutdown. On the same day, House Democrats released a series of private emails between Epstein, Ghislaine Maxwell, and journalist Michael Wolff.
== Morphologic patterns == Specific patterns of acute and chronic inflammation are seen during particular situations that arise in the body, such as when inflammation occurs on an epithelial surface, or pyogenic bacteria are involved.
== Awards and honors == United States National Academy of Sciences, member – 1942 Willard Gibbs Medal – 1943 American Philosophical Society, member – 1947 Albert Lasker Award for clinical medical research – 1952 American Academy of Arts and Sciences, member – 1953
== Applications == Due to the unique temperature-dependent phase transition experienced by ELPs, in which they move from a linear state to a spherical aggregate state above their Tt, as well as the ability of ELPs to be easily conjugated with other compounds, these biopolymers hold numerous applications. Some of these applications involve ELP use in protein purification, cancer therapy, and tissue scaffolding.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.